Business Context and Reporting Period
This Form 8-K was filed by Histogenics Corporation (trading symbol HSGX) on May 13, 2019, reporting events occurring on May 8, 2019. The Company is an emerging growth company incorporated in Delaware. The filing details a material asset sale and a lease termination, both contingent upon or related to a pending merger with Ocugen, Inc.
Key Financial Metrics and Transactions
- Asset Sale Proceeds: The Company agreed to sell substantially all assets related to its NeoCart program (including IP, licenses, and clinical data) to Medavate Corp. for a cash payment of $6.5 million.
- Lease Termination Costs: To terminate its lease for approximately 16,601 square feet in Lexington, Massachusetts, early (accelerating the end date from June 30, 2023, to June 30, 2019), the Company paid $300,000 and forfeited its full security deposit.
- Liquidity and Debt: The filing does not provide specific values for total cash, debt, or liquidity ratios. It only specifies the transactional cash inflow and outflow mentioned above.
Material Changes and Conditions
The $6.5 million asset sale is conditional upon the consummation of a merger between Histogenics Corporation and Ocugen, Inc., which requires stockholder approval. The lease termination is effective as of June 30, 2019, subject to conditions, though obligations may cease earlier if a new tenant occupies the premises.
Outlook, Risks, and Management Commentary
The primary risk identified is the contingency of the asset sale on the successful completion of the merger with Ocugen, Inc. If the merger does not close, the asset sale to Medavate Corp. will not proceed. The Company is divesting its NeoCart program assets, indicating a strategic shift or consolidation of operations pending the merger.
Key Facts for Investor Verification
- Verify the status of the merger agreement between Histogenics Corporation and Ocugen, Inc. dated April 5, 2019, as the asset sale is contingent upon its completion.
- Confirm the exact amount of the security deposit forfeited in the lease termination, as the filing states the "full amount" was retained by the landlord but does not specify the dollar value.
- Monitor the closing date of the asset sale to Medavate Corp. to determine when the $6.5 million cash inflow will be realized.
- Check for any updates on the lease termination if a new tenant is found prior to June 30, 2019, which would alter the Company's rent obligations.